We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Bristol-Myers Oversold Lung Cancer Drug, Investors Say

Law360 (February 12, 2018, 6:05 PM EST) -- Bristol-Myers Squibb Co. was slapped with a putative class action in California federal court on Friday, alleging company officials deceived investors about the prospects for its lung cancer drug, which resulted...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

California Northern

Nature of Suit

Securities/Commodities

Judge

Subscribers Only

Date Filed

February 9, 2018

Law Firms

Companies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.